MS Could Affect Survival Rate After Colorectal Cancer Diagnosis
According to a new study, people with multiple sclerosis (MS) who are diagnosed with colorectal cancer may be at a higher risk of dying from cancer or other causes over the next six months to one year than people with colorectal cancer who don’t have MS. The study was published in the September 15, 2021, online issue of Neurology, the medical journal of the American Academy of Neurology.
“These results warrant further investigation to determine what factors may lead to shorter survival times,” said study author Ruth Ann Marrie, MD, PhD, of the University of Manitoba in Winnipeg, Canada, and a member of the American Academy of Neurology. “Are people with MS less likely to receive cancer treatment? Or are they less able to tolerate the effects of chemotherapy? Are factors specific to MS involved? How accommodating is the cancer care system for people with disabilities? These are among the many questions that need to be investigated.”
For the study, researchers looked at health records for 338 people with MS and colorectal cancer who lived in Ontario and Manitoba, Canada. Each person was matched with four people who had colorectal cancer but did not have MS who were the same age and sex, and had the same year of cancer diagnosis, or 1,352 people. The participants were an average age of 65 when they were diagnosed with cancer.
The study found that people with MS were 45% more likely to die of any cause at six months after the cancer diagnosis than people without MS and 34% more likely to die of any cause at one year after diagnosis. After that point, the risk of death was the same for the two groups. People with MS were more likely to die of cancer than people without MS only at the six-month point after diagnosis, when their risk was 29% higher. The researchers adjusted for other factors that could affect risk of death, such as age, socioeconomic status and having other conditions like heart disease or diabetes.
Over five years, the fatality rate in Ontario was 16.4 deaths per 100 person-years for people with MS who died from any cause compared to 11.5 deaths for people without MS. Person-years take into account the number of people in a study, as well as the amount of time spent in the study. In Manitoba, those numbers were 19.8 deaths per 100 person-years for people with MS and 15.4 deaths for people without MS.
Looking at deaths due to cancer, the fatality rate was 12.7 deaths per 100 person-years for people with MS in Ontario, compared to 9.9 deaths for people without MS. In Manitoba, those numbers were 13.6 for people with MS and 13.0 for people without MS.
“Understanding more about the factors involved in treating cancer in people with MS and their outcomes will be helpful for people with MS and their doctors as they balance the benefits of cancer treatment with the potential adverse effects and consider life expectancy and quality of life,” Marrie said.
A limitation of the study was that researchers may not have accounted for all other conditions people may have had in addition to MS and colorectal cancer.
Call for Papers
ARO is seeking original case reports, research articles, and review articles on innovative topics offering practical applications in radiation oncology. Manuscripts undergo a double-blinded external peer review process, and there is no submission fee.
- First Clinical Results Published for 177Lu-rhPSMA-10.1 in mCRPC Trial
- Opaganib Shown to Protect Against Radiation-Induced Lung Inflammation
- Fusion Licenses Actinium-Based PSMA Targeted Radiotherapy From Heidelberg University and Euratom
- Future of Theranostics in Neurooncology Looks Promising With Recent Advancements
- First Cellular Therapy for Unresectable or Metastatic Melanoma Receives FDA Approval